Skip to main content

Table 1 Pain and sleep responses at different response levels and doses of pregabalin

From: Pregabalin in fibromyalgia - responder analysis from individual patient data

   Percent with treatment/placebo NNT (95% CI)
Outcome Level Placebo 300 mg 450 mg 600 mg 300 mg 450 mg 600 mg
Pain: change from baseline ≥ 0% 60 65 68 60 not calculated 13 (8.0 to 41) not calculated
6 weeks ≥ 15% 44 52 56 52 13 (7.8 to 43) 8.4 (5.8 to 15) 14 (7.6 to 67)
  ≥ 30% 28 36 39 39 10 (6.9 to 21) 8.0 (5.7 to 13) 8.5 (5.8 to 16)
  ≥ 50% 14 21 23 26 14 (8.8 to 30) 12 (7.9 to 22) 8.8 (6.2 to 15)
  ≥ 70% 4.1 7.7 9.0 12 30 (17 to 110) 19 (13 to 38) 14 (9.8 to 26)
Pain: change from baseline ≥ 0% 54 55 60 53 not calculated not calculated not calculated
12 weeks ≥ 15% 40 45 49 43 not calculated 12 (6.9 to 35) not calculated
  ≥ 30% 29 33 38 34 not calculated 11 (6.9 to 29) not calculated
  ≥ 50% 15 19 21 23 22 (11 to 870) 16 (9.3 to 59) 13 (8.1 to 31)
  ≥ 70% 5.9 6.8 8.5 12 not calculated not calculated 18 (11 to 43)
Sleep: change from baseline ≥ 0% 59 64 68 61 not calculated 11 (7.0 to 23) not calculated
6 weeks ≥ 15% 45 53 55 51 11 (7.2 to 29) 9.3 (6.3 to 18) 15 (8.0 to 130)
  ≥ 30% 29 39 43 41 9.4 (6.4 to 17) 6.8 (5.1 to 10) 8.2 (5.7 to 15)
  ≥ 50% 13 25 26 26 9.0 (6.6 to 14) 7.8 (5.9 to 12) 7.7 (5.7 to 12)
  ≥ 70% 3.8 11 13 13 14 (10 to 23) 11 (8.6 to 17) 12 (8.8 to 21)
Sleep: change from baseline ≥ 0% 51 54 58 52 not calculated 14 (7.6 to 68) not calculated
12 weeks ≥ 15% 37 43 49 44 not calculated 8.9 (5.9 to 19) 16 (8.3 to 170)
  ≥ 30% 25 32 40 35 14 (8.1 to 58) 7.0 (5.1 to 11) 10 (6.6 to 22)
  ≥ 50% 14 21 26 26 13 (8.2 to 30) 8.4 (6.0 to 14) 8.4 (6.1 to 14)
  ≥ 70% 5.0 9.3 10 12 24 (14 to 82) 20 (13 to 55) 14 (9.4 to 24)
  1. NNTs were not calculated when statistical significance was not achieved.